We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 40

Dietary Supplement & Cosmetics Legal Bulletin: November 2016
  • Shook Hardy & Bacon LLP
  • Canada, USA
  • November 30 2016

The Federal Trade Commission (FTC) has secured orders against 29 defendants whom it claims deceptively marketed and billed consumers for skin care


India ponders domestic impact of biopharma takeovers
  • Shook Hardy & Bacon LLP
  • India
  • March 10 2011

According to a news source, recent takeovers of India's key drug companies by foreign pharmaceutical interests have policymakers worried about the potential impact on domestic drug markets and prices


Moneytree report shows increased life sciences investments in Q1 2011
  • Shook Hardy & Bacon LLP
  • USA
  • May 19 2011

According to a PricewaterhouseCoopers report on venture capital investments, although fewer deals occurred in the first quarter of 2011 (Q1 2011) as compared to the last quarter of 2010, investment activity increased 5 percent overall


Pharma merger activity attributed to “patent cliff”
  • Shook Hardy & Bacon LLP
  • USA
  • November 18 2010

Noting that many of the pharmaceutical industry's best-selling products will soon lose their patent protection, industry analysts have reportedly suggested that the potential loss of nearly one-third of industry revenues in the near term could account for recent merger activity among the world's largest pharmaceutical companies


Indian officials to scrutinize pharmaceutical M&As
  • Shook Hardy & Bacon LLP
  • India
  • October 20 2011

Indian ministry officials have apparently decided that foreign companies may continue to invest in new pharmaceutical industry projects but that foreign proposals for mergers and acquisitions in this sector will have to undergo enhanced scrutiny


Molecular diagnostics company nets $27.7 million from common stock offering
  • Shook Hardy & Bacon LLP
  • USA
  • September 26 2013

Illinois-based Nanosphere, Inc. has reportedly closed a public offering of more than 17 million shares of common stock at $1.75 per share, including


NASDAQ Biotechnology Index surpasses all-time high in 1Q13
  • Shook Hardy & Bacon LLP
  • USA
  • May 16 2013

The NASDAQ Biotechnology Index reportedly rose in the first quarter of 2013 (1Q13) above levels last seen during the 2000 genomics bubble peakthe


Biotech investments rise in Q4 2012, but remain off for the year
  • Shook Hardy & Bacon LLP
  • USA
  • January 24 2013

Pricewatershouse Coopers LLP has released its fourth quarter (Q4) and final 2012 venture capital investment reports and notes that "Biotechnology


U.S. biotech sector shows IPO gains in 2013
  • Shook Hardy & Bacon LLP
  • USA
  • June 6 2013

According to Reuters, 14 biotech companies have gone public so far in 2013, marking a possible turnaround for the sector with a rising stock market


Biotech IPO boom continues
  • Shook Hardy & Bacon LLP
  • USA
  • August 1 2013

According to Xconomy's National Biotech Editor Luke Timmerman, the 24 biotech initial public offerings (IPOs) in 2013 are double those normally seen